PL3225243T3 - Sposób bezpiecznego i skutecznego leczenia i zapobiegania wtórnej nadczynności przytarczyc w przewlekłej chorobie nerek - Google Patents

Sposób bezpiecznego i skutecznego leczenia i zapobiegania wtórnej nadczynności przytarczyc w przewlekłej chorobie nerek

Info

Publication number
PL3225243T3
PL3225243T3 PL17158264.6T PL17158264T PL3225243T3 PL 3225243 T3 PL3225243 T3 PL 3225243T3 PL 17158264 T PL17158264 T PL 17158264T PL 3225243 T3 PL3225243 T3 PL 3225243T3
Authority
PL
Poland
Prior art keywords
safely
kidney disease
chronic kidney
effectively treating
secondary hyperparathyroidism
Prior art date
Application number
PL17158264.6T
Other languages
English (en)
Polish (pl)
Inventor
Charles W Bishop
Eric J Messner
Original Assignee
Opko Renal, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Renal, Llc filed Critical Opko Renal, Llc
Publication of PL3225243T3 publication Critical patent/PL3225243T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17158264.6T 2007-04-25 2008-04-25 Sposób bezpiecznego i skutecznego leczenia i zapobiegania wtórnej nadczynności przytarczyc w przewlekłej chorobie nerek PL3225243T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91385007P 2007-04-25 2007-04-25

Publications (1)

Publication Number Publication Date
PL3225243T3 true PL3225243T3 (pl) 2025-12-22

Family

ID=39926088

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17158264.6T PL3225243T3 (pl) 2007-04-25 2008-04-25 Sposób bezpiecznego i skutecznego leczenia i zapobiegania wtórnej nadczynności przytarczyc w przewlekłej chorobie nerek
PL18155042.7T PL3335712T3 (pl) 2007-04-25 2008-04-25 Sposób bezpiecznego i skutecznego leczenia i zapobiegania wtórnej nadczynności przytarczyc w przewlekłej chorobie nerek

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18155042.7T PL3335712T3 (pl) 2007-04-25 2008-04-25 Sposób bezpiecznego i skutecznego leczenia i zapobiegania wtórnej nadczynności przytarczyc w przewlekłej chorobie nerek

Country Status (13)

Country Link
US (3) US20100144684A1 (enExample)
EP (3) EP3225243B1 (enExample)
JP (5) JP2010525080A (enExample)
CA (1) CA2683514C (enExample)
DK (2) DK3225243T3 (enExample)
ES (2) ES3047207T3 (enExample)
FI (2) FI3225243T3 (enExample)
HR (2) HRP20251403T3 (enExample)
HU (1) HUE073014T2 (enExample)
PL (2) PL3225243T3 (enExample)
PT (2) PT3225243T (enExample)
SI (2) SI3225243T1 (enExample)
WO (1) WO2008134523A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
PT3095447T (pt) 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
DK2037936T3 (da) 2006-06-21 2014-09-22 Opko Renal Llc Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
EP2148685A4 (en) 2007-04-25 2010-07-28 Cytochroma Inc METHODS AND COMPOUNDS FOR THERAPY BASED ON VITAMIN D
KR101691876B1 (ko) 2007-04-25 2017-01-02 사이토크로마 인코포레이티드 비타민 d 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
ES3047207T3 (en) 2007-04-25 2025-12-03 Opko Renal Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
AU2009214049B2 (en) * 2008-02-13 2014-02-06 Dsm Ip Assets B.V. Combination of vitamin D and 25-hydroxyvitamin D 3
ES2593356T3 (es) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
JP5908402B2 (ja) * 2009-08-03 2016-04-26 ウィスコンシン・アルムニ・リサーチ・ファウンデーションWisconsin Alumni Research Foundation 腎疾患の予防方法およびその症状を処置する方法
US8518917B2 (en) * 2009-10-02 2013-08-27 Wisconsin Alumni Research Foundation 2-methylene-19-nor-vitamin D analogs and their uses
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
EP2648737B1 (en) 2010-12-06 2018-11-21 DSM IP Assets B.V. Treating conditions associated with increased eotaxin with 25-hydroxyvitamin d3
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CR20170085A (es) * 2014-08-07 2017-04-25 Opko Ireland Global Holdings Ltd Terapia adjuntiva con 25-hidroxi vitamina d
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
WO2017117712A1 (zh) * 2016-01-05 2017-07-13 富士通株式会社 信息传输方法、装置和系统
KR20180123100A (ko) 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
AU2018313853A1 (en) 2017-08-08 2020-01-02 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
CA3094915A1 (en) 2018-04-03 2019-10-10 Opko Ireland Global Holdings, Ltd. Use of calcifediol in bariatric surgery patients
KR20210126023A (ko) * 2019-02-06 2021-10-19 에어젠 파마 엘티디. 칼시페디올로 부갑상선 기능항진증의 진행을 조절하는 방법 및 이의 사용을 위한 조성물
CA3181945A1 (en) * 2020-05-31 2021-12-09 Eirgen Pharma Ltd. Hard capsule dosage form and uses thereof
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008517A2 (en) * 1996-08-26 1998-03-05 Takeda Chemical Industries, Ltd. Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
US3565924A (en) 1968-07-01 1971-02-23 Wisconsin Alumni Res Found 25-hydroxycholfcalciferol
US3833622A (en) 1969-03-17 1974-09-03 Upjohn Co Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds
US3974272A (en) * 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US3880894A (en) 1974-05-24 1975-04-29 Wisconsin Alumni Res Found 1,25-Dihydroxyergocalciferol
US4004003A (en) 1974-08-28 1977-01-18 The Upjohn Company 25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis
US4230701A (en) 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4335120A (en) 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
JPS5832823A (ja) 1981-08-20 1983-02-25 Chugai Pharmaceut Co Ltd 脱癌剤
US4721613A (en) 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
JPS59155309A (ja) 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンd↓3類組成物
US4684524A (en) 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4555364A (en) 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
US4695591A (en) 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4668517A (en) 1985-04-04 1987-05-26 Norwich Eaton Pharmaceuticals, Inc. Furazolidone dosage form
EP0207638B1 (en) 1985-06-04 1990-12-19 Teijin Limited Sustained-release pharmaceutical preparation
JPS61293911A (ja) 1985-06-24 1986-12-24 Teisan Seiyaku Kk 徐放化製剤
US5167965A (en) * 1987-02-09 1992-12-01 The Dow Chemical Company Palatable cholestyramine granules, tablets and methods for preparation thereof
US4997824A (en) 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5104864A (en) 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
JP2893191B2 (ja) 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
JPH02240024A (ja) 1989-03-13 1990-09-25 Ss Pharmaceut Co Ltd 活性型ビタミンd↓3類製剤用組成物
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
GB9004544D0 (en) 1990-03-01 1990-04-25 Leo Pharm Prod Ltd Novel treatment ii
JP2845342B2 (ja) 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンd▲下3▼誘導体含有固形製剤組成物
JP2893140B2 (ja) 1990-11-30 1999-05-17 エスエス製薬株式会社 安定なビタミンd製剤
JPH04288016A (ja) 1991-03-14 1992-10-13 Tokai Capsule Kk 活性型ビタミンd3類軟カプセル剤の製造方法
NZ242271A (en) 1991-04-09 1993-10-26 Takeda Chemical Industries Ltd Medicaments containing a vitamin d compound stabilised by a basic substance
US5693615A (en) 1991-06-05 1997-12-02 The Procter & Gamble Company Therapeutic compositions for osteoinduction
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5160742A (en) 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
DK0600079T3 (da) 1992-06-22 2002-04-15 Bone Care Int Inc Oral 1alpha-hydroxyprævitamin D
US5795882A (en) 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
US5354743A (en) * 1992-09-15 1994-10-11 Thys Jacobs Susan Method for the treatment of premenstrual syndrome with vitamin D
US5431917A (en) 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5342626A (en) 1993-04-27 1994-08-30 Merck & Co., Inc. Composition and process for gelatin-free soft capsules
JP2684587B2 (ja) 1993-06-21 1997-12-03 呉羽化学工業株式会社 腎性骨異栄養症における骨量減少抑制剤
US6121469A (en) 1993-12-23 2000-09-19 The Regents Of The University Of California Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs
JPH07242550A (ja) * 1994-03-02 1995-09-19 Teijin Ltd 二次性副甲状腺機能亢進症治療剤
IL110117A0 (en) 1994-06-24 1994-10-07 Univ Ben Gurion Pharmaceutical compositions comprising vitamin-d analogs
SE9402422D0 (sv) 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
WO1996003113A1 (en) 1994-07-22 1996-02-08 G.D. Searle & Co. Self-emulsifying drug delivery system
JPH0892098A (ja) 1994-09-27 1996-04-09 Teijin Ltd 肺結核治療剤
US5756123A (en) 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US6376479B1 (en) 1995-04-03 2002-04-23 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US20020183288A1 (en) 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
EP1021401A1 (en) 1995-09-21 2000-07-26 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
DE19549243A1 (de) 1995-12-21 1997-06-26 Schering Ag Pharmazeutische Präparate enthaltend Clathrate von Cyclodextrinen und nichtnatürliche Vitamin D-Analoga
US5958451A (en) 1996-09-03 1999-09-28 Yung Shin Pharm Ind. Co., Ltd. Process for producing porous, controlled-release capsules and encapsulated composition
ATE277739T1 (de) 1996-10-28 2004-10-15 Gen Mills Inc Einbettung und einkapselung von teilchen zur kontrollierten abgabe
JPH10158171A (ja) 1996-12-02 1998-06-16 Kita:Kk ビタミンd化合物を配合した眼内投与剤
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US20020128240A1 (en) 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6034075A (en) 1997-03-20 2000-03-07 The Trustees Of Columbia University In The City Of New York Method of treating polycystic ovarian syndrome
JPH1175863A (ja) 1997-07-10 1999-03-23 Kyowa Hakko Kogyo Co Ltd 25−ヒドロキシビタミンD3−1α−水酸化酵素および該酵素をコードするDNA
US20020076442A1 (en) 1997-09-02 2002-06-20 Martin Burke Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
JP2002509888A (ja) 1998-03-27 2002-04-02 オレゴン ヘルス サイエンシーズ ユニバーシティー 腫瘍および他の過増殖性疾患の治療におけるビタミンdおよびその類似体
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
SK287111B6 (sk) 1998-08-27 2009-12-07 Pharmacia & Upjohn Ab Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
US6139875A (en) 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
AU6283299A (en) 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
AU777977B2 (en) 1998-10-09 2004-11-04 General Mills Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
JP3449253B2 (ja) 1998-10-29 2003-09-22 シオノギクオリカプス株式会社 硬質カプセルの製造方法
JP2000206312A (ja) * 1998-11-12 2000-07-28 Olympus Optical Co Ltd 光学素子
DE69915346T2 (de) 1998-12-17 2004-07-22 Alza Corp., Mountain View Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6432936B1 (en) 1999-01-20 2002-08-13 Wisconsin Alumni Research Foundation Crystalline 1α-hydroxyvitamin D2 and method of purification thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ES2274785T3 (es) 1999-04-01 2007-06-01 Johns Hopkins University Analogos de 1-alfa,25-dihidroxi vitamina d3 no calcemicos, antiproliferativos, transcripcionalmente activos que contienen azufre.
DE19916419B4 (de) 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
WO2000072831A1 (en) * 1999-05-27 2000-12-07 Drugtech Corporation Nutritional formulations
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
DE60045101D1 (de) 1999-08-31 2010-11-25 Chugai Pharmaceutical Co Ltd Weichkapseln
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
US6375981B1 (en) 2000-06-01 2002-04-23 A. E. Staley Manufacturing Co. Modified starch as a replacement for gelatin in soft gel films and capsules
JP2004504295A (ja) * 2000-07-18 2004-02-12 ボーン ケア インターナショナル インコーポレイテッド 安定化1α−ヒドロキシビタミンD
WO2002017848A1 (fr) 2000-08-29 2002-03-07 Nisshin Kasei Co., Ltd. Capsule en dur
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
US6479649B1 (en) 2000-12-13 2002-11-12 Fmc Corporation Production of carrageenan and carrageenan products
HUP0304078A2 (hu) * 2001-05-15 2004-04-28 Warner-Lambert Co. Llc Tömörítési eljárás nátrium-fenitoin gyógyszerkészítmény előállítására
CA2452577C (en) 2001-07-05 2011-04-19 Wakunaga Pharmaceutical Co., Ltd. Soft capsules
US7033996B2 (en) 2001-08-31 2006-04-25 University Of Medicine & Dentistry Of New Jersey Method for the treatment of vitamin D related disease
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
DK1436257T3 (da) 2001-10-12 2007-06-25 Univ Johns Hopkins Oxim-analogica af 1-alpha, 25-dihydroxy-vitamin-D3 med ringe kalcemisk virkning
US7056655B2 (en) * 2001-11-02 2006-06-06 Scantibodies Laboratory, Inc. Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US6524788B1 (en) 2001-11-02 2003-02-25 Thomas L. Cantor Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
ITMI20012366A1 (it) 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
DE60238269D1 (de) 2001-11-22 2010-12-23 Morishita Jintan Co Nicht-gelatinöse Kapseln
CN100391464C (zh) 2001-12-03 2008-06-04 诺瓦西股份有限公司 含活性维生素d化合物的药物组合物
FR2829142B1 (fr) 2001-12-27 2004-02-13 Ulice Composition filmogene d'heteroxylanes pour la fabrication de capsules ainsi obtenues
US7632518B2 (en) 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
US6949256B2 (en) 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
NO20021592D0 (no) 2002-04-04 2002-04-04 Fmc Biopolymer As Polysakkaridkapsler og fremgangsmåte ved fremstilling derav
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US7101865B2 (en) 2002-06-13 2006-09-05 Cytochroma Inc. 24-sulfoximine vitamin D3 compounds
PL374922A1 (en) 2002-07-05 2005-11-14 Temrel Limited Controlled release composition
JP4500679B2 (ja) * 2002-07-29 2010-07-14 アルザ・コーポレーシヨン パリペリドンを制御送達する方法および投薬形態物
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
AU2002368245A1 (en) 2002-09-26 2004-04-19 Young-Kweon Choi Matrix type patch for transdermal administration of vitamin d analog and the use thereof
US20050101576A1 (en) 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US8999372B2 (en) 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
JP2004175750A (ja) 2002-11-28 2004-06-24 Kose Corp 皮膚障害抑制剤、皮膚障害改善剤、及びそれらを含有する皮膚外用剤
GB2411116B (en) 2002-12-16 2009-04-29 Teva Pharma Increasing the bioavailability of alendronate by predose administration of alphacalcidol
KR20050123097A (ko) * 2003-02-11 2005-12-29 알자 코포레이션 변형된 층 형상을 갖는 방법 및 제형
US7816341B2 (en) 2003-04-14 2010-10-19 Fmc Corporation Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
WO2004091537A2 (en) 2003-04-14 2004-10-28 Fmc Corporation Process for making gel films
EP1622455A4 (en) * 2003-04-30 2009-12-16 Bioxell Spa GEMINI VITAMIN D3 COMPOUNDS AND METHOD FOR THEIR USE
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
ES2523454T3 (es) 2003-06-16 2014-11-26 Solx, Inc. Derivación para el tratamiento del glaucoma
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US20050148557A1 (en) 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
AU2004275815A1 (en) * 2003-09-24 2005-04-07 Bioxell S.P.A. 1,3-diaclyated,26,27-alkyl/haloalkyl vitamin D3 compounds and methods of use thereof
WO2005051396A2 (en) * 2003-11-25 2005-06-09 Deltanoid Pharmaceuticals, Inc. Methods for reducing body fat using vitamin d compounds
US20060009425A1 (en) 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
JP2008502605A (ja) 2004-06-16 2008-01-31 スマート ドラッグ システムズ インコーポレイティド 徐放性ワクチン組成物
US20050287213A1 (en) 2004-06-28 2005-12-29 Wong Patrick S Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents
US20060019933A1 (en) 2004-07-22 2006-01-26 David Boardman Process for preparing stabilized vitamin D
WO2006010640A1 (en) 2004-07-29 2006-02-02 Sanofi-Aventis Pharmaceutical multilayer tablet for controlled release of active ingredients with highly ph-dependent solubility
US20060134225A1 (en) * 2004-10-15 2006-06-22 Moerck Rudi E Phosphate binder with reduced pill burden
US8231896B2 (en) 2004-11-08 2012-07-31 R.P. Scherer Technologies, Llc Non-gelatin soft capsule system
CN101316865B (zh) 2004-12-03 2012-01-25 科学与工业研究委员会 由半精制κ角叉菜聚糖制备生物可降解膜的方法
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US7745226B2 (en) 2005-04-06 2010-06-29 Quest Diagnostics Investments Incorporated Methods for detecting vitamin D metabolites
US8241664B2 (en) 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US20060257481A1 (en) 2005-04-21 2006-11-16 Decode Genetics Ehf. Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy
US20080134937A1 (en) 2005-05-25 2008-06-12 Joo Hwan Yang Cellulose hard capsule enhancing mechanical film strength
AR055099A1 (es) 2005-07-28 2007-08-08 Alza Corp Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
CA2624124A1 (en) 2005-09-29 2007-04-12 F. Hoffmann-La Roche Ag Antibodies against 25-hydroxyvitamin d
ITFI20050206A1 (it) 2005-09-30 2007-04-01 Valpharma Sa Composizione farmaceutica a rilascio controllato di venlafaxina cloridrato, e processo per la sua preparazione
US20070122477A1 (en) * 2005-10-12 2007-05-31 Cytochroma, Inc. Methods and articles for treating 25-hydroxyvitamin D insufficiency and deficiency
CN101351196B (zh) 2005-10-26 2013-07-03 班纳制药公司 作为胶囊填充物的基于亲脂性载体的双重控释基质系统
JP5406530B2 (ja) 2005-10-26 2014-02-05 バナー ファーマキャプス, インコーポレイテッド 親水性ベヒクルに基づく二重制御された放出マトリクスシステム
CN103772520B (zh) 2005-11-01 2018-04-10 Cp凯尔科美国股份有限公司 高粘度迪优坦胶及其制备方法
WO2007068287A1 (en) 2005-12-15 2007-06-21 Laboratoria Qualiphar Sustained release vitamin preparation
PT3095447T (pt) 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
CA2660613A1 (en) 2006-06-06 2007-12-21 Fmc Corporation Kappa-2 carrageenan composition and products made therefrom
DK2037936T3 (da) * 2006-06-21 2014-09-22 Opko Renal Llc Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
CA2667167C (en) 2006-10-27 2014-02-18 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
WO2008097646A1 (en) 2007-02-09 2008-08-14 Schering Corporation Methods to treat and/or prevent mucositis
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
KR101691876B1 (ko) 2007-04-25 2017-01-02 사이토크로마 인코포레이티드 비타민 d 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
ES3047207T3 (en) 2007-04-25 2025-12-03 Opko Renal Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
DE102008006203B4 (de) * 2008-01-26 2011-03-17 Jost-Werke Gmbh Fahrzeugkupplung zum Herstellen einer mechanischen Verbindung zwischen einem ersten und einem zweiten Fahrzeug
AU2009214054B2 (en) 2008-02-13 2014-12-18 Dsm Ip Assets B.V. Use of 25-hydroxy-vitamin D3 to affect human muscle physiology
AU2009214049B2 (en) 2008-02-13 2014-02-06 Dsm Ip Assets B.V. Combination of vitamin D and 25-hydroxyvitamin D 3
DK2321273T3 (en) 2008-07-24 2015-02-16 Wisconsin Alumni Res Found Once weekly administration of 25-hydroxy vitamin D 3 for maintaining an elevated blood level concentration at steady state pharmaco-kinetics
KR101528957B1 (ko) 2008-09-24 2015-06-17 에보니크 룀 게엠베하 에탄올의 영향에 대하여 내성을 갖는 ph-의존성 조절 방출 제약학적 오피오이드 조성물
WO2011031621A2 (en) 2009-09-10 2011-03-17 Fmc Corporation High strength seamless alginate capsules
US8101203B2 (en) 2010-01-14 2012-01-24 Karl Wei Cao Hard capsule composition and method of use
US8101204B2 (en) 2010-01-14 2012-01-24 Karl Wei Cao Hard capsule composition and method of use
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
CN103228269B (zh) 2010-08-04 2015-06-17 R·P·舍勒科技有限责任公司 软胶囊用成膜组合物
EP2648737B1 (en) 2010-12-06 2018-11-21 DSM IP Assets B.V. Treating conditions associated with increased eotaxin with 25-hydroxyvitamin d3
ES2614817T3 (es) 2010-12-28 2017-06-02 Future Diagnostics B.V. Reactivo de liberación para vitamina D
DK2680826T3 (en) 2011-03-02 2017-10-09 D3 Pharma Ltd VITAMIN D COMPOSITION
ES2617654T3 (es) 2011-04-20 2017-06-19 Suheung Co., Ltd. Composición de la cubierta de cápsula blanda de origen no animal que tiene dureza de la cubierta y desintegración, mejoradas
CN102771688A (zh) 2011-05-13 2012-11-14 富曼实(上海)商贸有限公司 可食用液体填充的多糖胶囊
EP2815745A1 (en) 2013-06-21 2014-12-24 Swiss Caps Rechte und Lizenzen AG Soft shell capsule and process for its manufacture
CN103495176B (zh) 2013-10-26 2015-01-28 中山市凯博思淀粉材料科技有限公司 一种共混挤出法制备淀粉基软胶囊的方法
CN103520133B (zh) 2013-10-26 2015-02-04 中山市凯博思淀粉材料科技有限公司 一种淀粉基软胶囊的制备方法

Also Published As

Publication number Publication date
US20140274977A1 (en) 2014-09-18
JP2014098034A (ja) 2014-05-29
DK3335712T3 (da) 2025-10-20
ES3044311T3 (en) 2025-11-26
CA2683514C (en) 2019-07-09
HRP20251194T3 (hr) 2026-01-30
ES3047207T3 (en) 2025-12-03
EP2148683A1 (en) 2010-02-03
EP3335712B1 (en) 2025-09-10
FI3335712T3 (fi) 2025-10-23
SI3335712T1 (sl) 2026-01-30
FI3225243T3 (fi) 2025-10-13
JP2010525080A (ja) 2010-07-22
SI3225243T1 (sl) 2025-11-28
CA2683514A1 (en) 2008-11-06
US11801253B2 (en) 2023-10-31
PT3225243T (pt) 2025-10-01
JP2018009040A (ja) 2018-01-18
JP2017075183A (ja) 2017-04-20
EP3225243A1 (en) 2017-10-04
WO2008134523A1 (en) 2008-11-06
US20100144684A1 (en) 2010-06-10
PT3335712T (pt) 2025-10-23
HRP20251403T3 (hr) 2026-02-27
HUE073014T2 (hu) 2025-12-28
EP3335712A1 (en) 2018-06-20
PL3335712T3 (pl) 2025-12-22
EP2148683A4 (en) 2012-09-12
EP3225243B1 (en) 2025-09-03
JP2019196402A (ja) 2019-11-14
US20180021355A1 (en) 2018-01-25
DK3225243T3 (da) 2025-09-29

Similar Documents

Publication Publication Date Title
PT3335712T (pt) Método de tratamento e prevenção seguro e eficaz do hiperparatiroidismo secundário na doença renal crónica
ZA201003386B (en) Systems and methods for water treatment
PT2037936E (pt) Método de tratamento e prevenção do hiperparatiroidismo secundário
IL193099A0 (en) Method of treating chronic kidney disease
EP1999077A4 (en) SYSTEM AND METHOD FOR TREATING WASTEWATER
SG10201610076SA (en) Method and system for treating ballast water
EP2382010A4 (en) METHOD AND SYSTEMS FOR FAT REDUCTION AND / OR TREATMENT OF CELLULITE
IL195400A0 (en) Aldh-2 inhibitors in the treatment of addiction
ZA200805958B (en) Compositions and methods for preventing or treating feline chronic kidney disease
ZA201102035B (en) Methods and formulations for treating chronic liver disease
EP2170311A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES
SI2520295T1 (sl) Postopki za preprečevanje in zdravljenje mukozitisa
IL184441A0 (en) Method and device for water treatment
IL204728A0 (en) Methods and compounds for treating retinol-related diseases
EP2114467A4 (en) BIOCIDAL COMPOSITION AND PROCESS FOR TREATING RECYCLED WATER SYSTEMS
EP2049899A4 (en) METHOD FOR THE PREVENTION AND TREATMENT OF DISEASES
IL202307A0 (en) Multikinase inhibitors for use in the treatment of cancer
EP2227439A4 (en) SYSTEM AND METHOD FOR STORAGE AND TREATMENT OF WASTEWATER
ZA200808076B (en) Methods for preventing and treating amyloidogenic diseases
EP2143821A4 (en) DISCHARGE SURFACE TREATMENT METHOD AND REPAIR METHOD
GB2459206B (en) Laminate and method of edge treatment therefor
ZA200902533B (en) Methods for treating and reducing the incidence of Newcastle disease
GB0617505D0 (en) Pneumothorax treatment apparatus and methods
ZA201200065B (en) Water treatment method and system
SI2225012T1 (sl) Postroj za obdelavo odpadne vode in postopek za obdelavo odpadne vode